Diabetes and Endothelial Function: Implications for Coronary Angioplasty

  • Todd J. Anderson
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 498)


Complications from coronary artery disease remain the leading cause of mortality in subjects with diabetes mellitus. As such, coronary revascularization is frequently performed in patients with diabetes. Percutaneous coronary intervention has been widely applied to patients with coronary disease including those with diabetes.1Whereas success rates remain high it is clear that outcomes in patients with diabetes are worse than those without diabetes. Kip et al. reported on the 9 year follow-up from the 1985-86 NHLBI angioplasty registry.2Patients with diabetes tended to be older, were more likely to be female, have more extensive coronary disease and have greater comorbidity. Despite this, acute success and the degree of revascularization were the same, but in-hospital events were higher. The 9 year mortality was almost twice as high in those with diabetes (35.9 vs 17.9%). Similarly, there was an excess of non-fatal myocardial infarctions, coronary bypass surgery and repeat angioplasty. Diabetes remained a significant independent risk factor in multivariate analysis. Similar long-term registry data has been reported by others.3;4


Balloon Angioplasty Coronary Stenting Bypass Angioplasty Revascularization Investigation Intravascular Ultrasound Study Bovine Aortic Smooth Muscle Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Topol EJ, Serruys PW: Frontiers in interventional cardiology.Circulation1998;98:1802–1820PubMedCrossRefGoogle Scholar
  2. 2.
    Kip KE, Faxon DP, Detre KM, Yeh W, Kelsey SF, Currier JW: Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry.Circulation 1996;94:1818–1825 PubMedCrossRefGoogle Scholar
  3. 3.
    Barsness GW, Peterson ED, Ohman EM, Nelson CL, DeLong ER, Reyes JG, Smith PK, Anderson RD, Jones RH, Mark DB, Califf RM: Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty.Circulation1997;96:2551–2556PubMedCrossRefGoogle Scholar
  4. 4.
    Stein B, Weintraub WS, Gebhart SP, Cohen-Bernstein CL, Grosswald R, Liberman HA, Douglas JSJ, Morris DC, King SB: Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty.Circulation1995;91:979–989PubMedCrossRefGoogle Scholar
  5. 5.
    Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx GR, Emanuelsson H, Marco J, Legrand V, Materne P, Belardi J, Sigwart U, Colombo A, Goy JJ, van den Heuvel P, Delcan J, Morel MA, for the BENESTENT Study Group: A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease.N Engl J Med 1994;331:489–495 PubMedCrossRefGoogle Scholar
  6. 6.
    Van Belle E, Bauters C, Hubert E, Bodart JC, Abolmaali K, Meurice T, McFadden EP, Lablanche JM, Bertrand ME: Restenosis rates in diabetic patients: a comparison of coronary stenting and balloon angioplasty in native coronary vessels.Circulation1997;96:1454–1460PubMedCrossRefGoogle Scholar
  7. 7.
    Elezi S, Kastrati A, Pache J, Wehinger A, Hadamitzky M, Dirschinger J, Neumann FJ, Schomig A: Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. AmColl Cardio11998;32:1866–1873CrossRefGoogle Scholar
  8. 8.
    Kornowski R, Mintz GS, Kent KM, Pichard AD, Satler LF, Bucher TA, Hong MK, Popma JJ, Leon MB: Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimai hyperplasia. A serial intravascular ultrasound study.Circulation1997;95:1366–1369PubMedCrossRefGoogle Scholar
  9. 9.
    The BARI Investigators: Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI).Circulation1997;96:1761–1769CrossRefGoogle Scholar
  10. 10.
    .Detre KM, Guo P, Holubkov R, Califf RM, Sopko G, Bach R, Brooks MM, Bourassa MG, Shemin RJ, Rosen AD, Krone RJ, Frye RL, Feit F: Coronary revascularization in diabetic patients: A comparison of the randomized and observational components of the bypass angioplasty revascularization investigation (BARI).Circulation 1999;99:633–640 PubMedCrossRefGoogle Scholar
  11. 11.
    Weintraub WS, Stein B, Kosinski AS, Douglas JS, Jr., Ghazzal ZMD, Jones EL, Morris DC, Guyton RA, Craver JS, King SB, III: Outcome of coronary bypass surgery versus coronary angioplasty in diabetic patients with multivessel coronary artery disease.J Am Coll Cardiol1998;31:10–19PubMedCrossRefGoogle Scholar
  12. 12.
    Keaney JFJ, Loscalzo J: Diabetes, oxidative stress, and platelet activation [In Process Citation].Circulation1999;99:189–191PubMedCrossRefGoogle Scholar
  13. 13.
    Kleiman NS, Lincoff AM, Kereiakes DJ, Miller DP, Aguirre FV, Anderson KM, Weisman HF, Califf RM, Topol EJ: Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators.Circulation1998;97:1912–1920PubMedCrossRefGoogle Scholar
  14. 14.
    Aronson D, Bloomgarden Z, Rayfield EJ: Potential mechanisms promoting restenosis in diabetic patients.J Am Coll Cardiol1996;27:528–535PubMedCrossRefGoogle Scholar
  15. 15.
    Banskota NK, Taub R, Zellner K, King GL: Insulin, insulin-like growth factor I and platelet-derived growth factor interact additively in the induction of the protoncogene c-myc and cellular proliferation in cultured bovine aortic smooth muscle cells.Mol Endocrino!1989;3:1183–1190CrossRefGoogle Scholar
  16. 16.
    Tamaroglio TA, Lo GS: Regulation of fibronectin by insulin-like growth factor-1 in cultured rat thoracic aortic smooth muscle cells and glomerular mesangial cells.Exp Cell Res1994;215:338–346PubMedCrossRefGoogle Scholar
  17. 17.
    Xi XP, Graf K, Goetze S, Fleck E, Hsueh WA, Law RE: Central role of the MAPK pathway in ang 11-mediated DNA synthesis and migration in rat vascular smooth muscle cells.Arteriosclerosis,Thrombosis & Vascular Biology.1999;19:73–82CrossRefGoogle Scholar
  18. 18.
    Mick MJ, Piedmonte MR, Arnold AM, Simpfendorfer C: Risk stratificication for long-term outcome after elective coronary angioplasty: a multivariate analysis of 5000 patients.JAm Coll Cardiol1994;24:74–80CrossRefGoogle Scholar
  19. 19.
    Reaven GM: Role of insulin resistance in human disease.Diabetes1988;37:1595–1607PubMedCrossRefGoogle Scholar
  20. 20.
    Wilson PWF, Kannel WB, Silbershatz H, D’Agostino RB: Clustering of metabolic factors and coronary heart disease.Archives of Internal Medicine1999;159:1104–1109PubMedCrossRefGoogle Scholar
  21. 21.
    Kannel WB, McGee DL: Diabetes and glucose tolerance as risk factors for cardiovascular disease:the Framingham Study.Diabetes Care1979;2:120–126PubMedCrossRefGoogle Scholar
  22. 22.
    Gerstein HC, Pais P, Pogue J, Yusuf S: Relationship of glucose and insulin levels to the risk of myocardial infarction:A case-control study.JAm Coll Cordial1999;33:612–619CrossRefGoogle Scholar
  23. 23.
    Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) [see comments] [published erratum appears in Diabetes Care 1997 Jun; 20(6):1048].Diabetes Care1997;20:614–620PubMedCrossRefGoogle Scholar
  24. 24.
    Moncada S, Higgs A: The 1-arginine-NO pathway.N Engl J Med1993;329:2002–2012Google Scholar
  25. 25.
    Furchgott RF, Zawadski JV: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine.Nature1980;288:373–376PubMedCrossRefGoogle Scholar
  26. 26.
    Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD: Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release.Journal of Clinical Investigation1994;94:1172–1179PubMedCrossRefGoogle Scholar
  27. 27.
    Williams SB, Cusco JA, Roddy M-A, Johnstone M, Creager MA: Impaired nitric oxide-mediated vasodilation in humans with non-insulin-dependent diabetes mellitus.JACC1996;27:567–574PubMedCrossRefGoogle Scholar
  28. 28.
    Johnstone M, Creager SJ, Scales K, Cusco JA, Lee B, Creager MA: Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus.Circulation1993;88:2510–1516PubMedCrossRefGoogle Scholar
  29. 29.
    Smits P, Kapma J-A, Jacobs M-C, Lutterman J, Thien T: Endothelium-dependent vascular relaxation in patients with type I diabetes.Diabetes1993;42:148–153PubMedCrossRefGoogle Scholar
  30. 30.
    Steinberg HO, Chaker H, Learning R, Johnson A, Brechtel G, Baron AD: Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance.Journal of Clinical Investigation1996;97:2601–2610PubMedCrossRefGoogle Scholar
  31. 3E.
    Steinberg HO, Tarshoby M, Monestel R, Hook G, Cronin J, Johnson A, Bayazeed B, Baron AD: Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation.Journal of Clinical Investigation1997;100:1230–1239PubMedCrossRefGoogle Scholar
  32. 32.
    Tsao PS, Niebauer J, Buitrago R, Lin PS, Wang B, Cooke JP, Chen Y, Reaven GM: Interaction of diabetes and hypertension on determinants of endothelial adhesiveness.Arterioscler Thromb Vasc Biol1998;18:947–953PubMedCrossRefGoogle Scholar
  33. 33.
    Cosentino F, Hishikawa K, Katusic ZS, Luscher TF: High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells.Circulation1997;96:25–28PubMedCrossRefGoogle Scholar
  34. 34.
    Williams SB, Goldfine AB, Timimi FK, Ting HH, Roddy M-A, Simonson DC, Creager MA: Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo.Circ1998;97:1695–1701CrossRefGoogle Scholar
  35. 35.
    Davi G, Ciabattoni G, Consoli A, Mezzetti A, Falco A, Santarone S, Pennese E, Vitacolonna E, Bucciarelli T, Costantini F, Capani F, Patrono C: In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation [In Process Citation].Circulation1999;99:224–229PubMedCrossRefGoogle Scholar
  36. 36.
    Vlassara H, Fuh H, Makita Z, Krungkrai S, Cerami A, Bucala R: Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications.Proc Natl Acad Sci USA1992;89:12043–12047PubMedCrossRefGoogle Scholar
  37. 37.
    Anderson TJ, Shewchuk L, Buller CE, Carere R, Teefy P: Endothelium-dependent resistance vessel function is impaired immediately following coronary intervention.Can J Cardiol1998;188F(Abstract)Google Scholar
  38. 38.
    Merhi Y, Provost P, Guidoin R, Latour JG: Importance of platelets in neutrophil adhesion and vasoconstriction after deep carotid arterial injury by angioplasty in pigs.Arterioscler Thromb Vasc Biol1997;17:1185–1191PubMedCrossRefGoogle Scholar
  39. 39.
    The EPISTENT Investigators: Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/Ills blockade.Lancet1998;352:87–92Google Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Todd J. Anderson
    • 1
  1. 1.University of CalgaryCalgaryCanada

Personalised recommendations